Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Rapport sur les actions

Capitalisation boursière : CN¥40.5b

Haisco Pharmaceutical Group Résultats passés

Passé contrôle des critères 3/6

Haisco Pharmaceutical Group's earnings have been declining at an average annual rate of -13.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 2.2% per year. Haisco Pharmaceutical Group's return on equity is 13.1%, and it has net margins of 12.8%.

Informations clés

-13.2%

Taux de croissance des bénéfices

-13.6%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie10.9%
Taux de croissance des recettes-2.2%
Rendement des fonds propres13.1%
Marge nette12.8%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Recent updates

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Jul 04
Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Jun 17
Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Mar 19
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Feb 27
Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Ventilation des recettes et des dépenses

Comment Haisco Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

SZSE:002653 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 243,7224761,645553
30 Jun 243,6723851,638522
31 Mar 243,4843581,566509
31 Dec 233,3552951,522517
30 Sep 233,3023751,585512
30 Jun 233,1382821,534477
31 Mar 233,0772801,509453
01 Jan 233,0152771,465448
30 Sep 222,9591731,403425
30 Jun 222,744951,325417
31 Mar 222,607841,256425
01 Jan 222,7733451,331431
30 Sep 212,8665091,355471
30 Jun 213,1547281,444486
31 Mar 213,4697961,626447
31 Dec 203,3306371,585406
30 Sep 203,3265131,707317
30 Jun 203,5204881,790259
31 Mar 203,6875721,875244
31 Dec 193,9374941,973235
30 Sep 194,3294131,887236
30 Jun 194,1054231,837229
31 Mar 193,7883231,630214
31 Dec 183,4273331,511204
30 Sep 182,6243371,320128
30 Jun 182,208247989184
31 Mar 182,0612541,024152
31 Dec 171,856238939119
30 Sep 171,8063351,02296
30 Jun 171,6063411,0200
31 Mar 171,5354448870
31 Dec 161,4364437770
30 Sep 161,3424065960
30 Jun 161,3263955880
31 Mar 161,1473154650
31 Dec 151,2123724520
30 Sep 151,1793724310
30 Jun 151,2334344210
31 Mar 151,2264694300
01 Jan 151,2114514350
30 Sep 141,1105203610
30 Jun 141,0675243240
31 Mar 141,0315202970
31 Dec 139925192870

Des revenus de qualité: 002653 has a large one-off gain of CN¥116.9M impacting its last 12 months of financial results to 30th September, 2024.

Augmentation de la marge bénéficiaire: 002653's current net profit margins (12.8%) are higher than last year (11.3%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: 002653's earnings have declined by 13.2% per year over the past 5 years.

Accélération de la croissance: 002653's earnings growth over the past year (27.1%) exceeds its 5-year average (-13.2% per year).

Bénéfices par rapport au secteur d'activité: 002653 earnings growth over the past year (27.1%) exceeded the Pharmaceuticals industry -1.2%.


Rendement des fonds propres

ROE élevé: 002653's Return on Equity (13.1%) is considered low.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé